I-Mab Announces Underwritten Offering of ADSs
Ticker: NBP · Form: 6-K · Filed: Aug 4, 2025 · CIK: 1778016
| Field | Detail |
|---|---|
| Company | I-Mab (NBP) |
| Form Type | 6-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, capital-raise, underwriting
TL;DR
I-Mab is selling 33.3M ADSs via underwritten offering led by Leerink Partners.
AI Summary
On August 1, 2025, I-Mab entered into an underwriting agreement with Leerink Partners LLC for an underwritten offering of 33,333,330 American Depositary Shares (ADSs). Each ADS represents twenty-three ordinary shares. The offering is being conducted by the company.
Why It Matters
This filing indicates I-Mab is raising capital through a public offering, which could fund its operations and research, potentially impacting its stock price.
Risk Assessment
Risk Level: medium — Underwritten offerings can dilute existing shareholders and signal a need for capital, which may be viewed negatively by the market.
Key Numbers
- 33,333,330 — ADSs Offered (Represents the total number of American Depositary Shares being issued in the underwritten offering.)
Key Players & Entities
- I-Mab (company) — Issuer of ADSs
- Leerink Partners LLC (company) — Representative of the underwriters
- 33,333,330 (dollar_amount) — Number of ADSs to be offered
- August 1, 2025 (date) — Date of underwriting agreement
FAQ
What is the total number of American Depositary Shares (ADSs) I-Mab is offering?
I-Mab is offering 33,333,330 ADSs.
Who is the lead underwriter for this offering?
Leerink Partners LLC is the representative of the several underwriters.
On what date did I-Mab enter into the underwriting agreement?
The underwriting agreement was entered into on August 1, 2025.
What does each American Depositary Share (ADS) represent?
Each ADS represents twenty-three (23) ordinary shares of I-Mab.
What type of offering is this?
This is an underwritten offering.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 4, 2025 regarding I-Mab (NBP).